- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02494726
Prospective Analysis of the Use of TEG in Stroke Patients (TEG)
Prospective Analysis of the Use of Thromboelastography in Stroke Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Thromboelastography (TEG), a computerized analysis that has been used since the 1940s, is the only stand alone test that can provide integrated information on the balance between the two separate but simultaneously occuring components of coagulation, thrombosis and lysis. It measures the coagulation process from initial clotting cascade to clot strength.
TEG may be used to assess the coagulation status of patients with acute stroke, whether ischemic or hemorrhagic. TEG might also be a useful way to predict and assess the degree of fibrinolysis that is achieved by tissue plasminogen activator (tPA). Currently tPA is given as a standard dose determined by the patient's body weight, thus given the variability in patient outcome after tPA, this dose could sometimes be too small or too large, leading to thrombolysis or bleeding, respectively. One of the purposes of this observational study is to evaluate how effective TEG is on predicting and assessing the degree of thrombolysis following tPA therapy, by producing a range of TEG values correlated with optimal thrombolysis.
The results of the recent FAST trial demonstrated the need to identify patients with spontaneous intracerebral hemorrhage (ICH) who are at increased risk for hematoma enlargement. Such identified patients, could benefit from a therapeutic advantage of activated factor VII or other hemostatic agents may be more clearly studied. Therefore, another purpose of this study is to evaluate how effective TEG is on predicting further bleeding for patients with spontaneous ICH.
The study will consist of 208 ischemic patients and 80 hemorrhagic patients, whom which are approached from all stroke patients admitted to Memorial Hermann Hospital Emergency Department receiving a confirmatory CT or MRI scan. Patients who agree to participate will have blood drawn the day of hospital arrival, will then be followed for 36 +/- 12 hours after the stroke, and 90 +/- 30 days after the stroke, all during which two more blood samples will be obtained.
Normal controls will be age and sex matched to the investigators' research population. A one-time blood draw will be obtained and information collected will be age, sex and TEG values.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- The University of Texas Medical School at Houston
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- At least 18 years of age or older.
- Symptoms and signs causing measurable neurologic deficit consistent with an acute stroke.
- CT or MRI consistent with stroke (ischemic or hemorrhagic) or with clinical evidence suggesting a stroke.
- For acute ischemic stroke patients, treatment with tPA and TEG blood draw must be done within 4.5 hours of symptom onset.
- For ICH patients, TEG blood draw must be done within 6 hours of symptom onset.
Exclusion Criteria:
- Contraindication to CT and MRI (ex. inability to lie flat)
- If ICH patient
- Hemorrhage secondary to trauma, arteriovenous malformation (AVM) or crush injury
- Planned surgical evacuation (hemicraniectomy and ventriculostomy allowed).
- Receipt of hemostatic agents (FFP, Cryo, activated factor seven) prior to TEG blood draw.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Ischemic Stroke
Ischemic stroke patients who have had blood analyzed using thromboelastography (TEG)
|
TEG (Thrombelastography) measurements include: Split Point (SP) is the time elapsed for the clot to initially form fibrin when the blood is first placed in the TEG machine.
Reaction Time (R) is the time elapsed from its initial fibrin formation until the clot reaches 2mm.
K is the time measured from R until the level of clot firmness reaches 20mm, measuring the speed of clot strengthening.
These are measured in minutes.
Delta measures if the formation of the clot has been suppressed; measured as the difference between R and SP.
Angle reflects the speed at which clots form by forming the slope of the TEG tracing at R from the horizontal line.
Maximum Amplitude (MA) in mm is the measure of maximum strength of the clot, true platelet function.
G is the measure of the clot firmness; measured by a formula (G=(5000*MA)/(100-MA) in dynes/cm2).
LY30 is a measure of clot lysis at 30 minutes after MA is reached.
Other Names:
|
Healthy Controls
Healthy controls who have had their blood analyzed using thromboelastography (TEG)
|
TEG (Thrombelastography) measurements include: Split Point (SP) is the time elapsed for the clot to initially form fibrin when the blood is first placed in the TEG machine.
Reaction Time (R) is the time elapsed from its initial fibrin formation until the clot reaches 2mm.
K is the time measured from R until the level of clot firmness reaches 20mm, measuring the speed of clot strengthening.
These are measured in minutes.
Delta measures if the formation of the clot has been suppressed; measured as the difference between R and SP.
Angle reflects the speed at which clots form by forming the slope of the TEG tracing at R from the horizontal line.
Maximum Amplitude (MA) in mm is the measure of maximum strength of the clot, true platelet function.
G is the measure of the clot firmness; measured by a formula (G=(5000*MA)/(100-MA) in dynes/cm2).
LY30 is a measure of clot lysis at 30 minutes after MA is reached.
Other Names:
|
Hemorrhagic Stroke
Intracerebral hemorrhage patients who have had their blood analyzed by thromboelastography (TEG)
|
TEG (Thrombelastography) measurements include: Split Point (SP) is the time elapsed for the clot to initially form fibrin when the blood is first placed in the TEG machine.
Reaction Time (R) is the time elapsed from its initial fibrin formation until the clot reaches 2mm.
K is the time measured from R until the level of clot firmness reaches 20mm, measuring the speed of clot strengthening.
These are measured in minutes.
Delta measures if the formation of the clot has been suppressed; measured as the difference between R and SP.
Angle reflects the speed at which clots form by forming the slope of the TEG tracing at R from the horizontal line.
Maximum Amplitude (MA) in mm is the measure of maximum strength of the clot, true platelet function.
G is the measure of the clot firmness; measured by a formula (G=(5000*MA)/(100-MA) in dynes/cm2).
LY30 is a measure of clot lysis at 30 minutes after MA is reached.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Baseline TEG in patients with spontaneous ICH vs age matched controls
Time Frame: TEG obtained within 6 hours of last seen normal in patients with spontaneous ICH
|
Compare baseline (within 6 hours of last seen normal) TEG in patients with spontaneous ICH to TEG in age-matched controls.
|
TEG obtained within 6 hours of last seen normal in patients with spontaneous ICH
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rapid clinical improvement after tPA (8 or greater point improvement on NIHSS score or total NIHSS 0 or 1)
Time Frame: Change in NIHSS score from baseline (prior to IV tPA within 4.5 hours of last seen normal) to NIHSS 36 +/- 12 hours after last seen normal.
|
Correlate baseline (within 4.5 hours of last seen normal and prior to tPA) and 10 minute post tPA TEG values with rapid clinical improvement
|
Change in NIHSS score from baseline (prior to IV tPA within 4.5 hours of last seen normal) to NIHSS 36 +/- 12 hours after last seen normal.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hematoma enlargement in patients with spontaneous ICH
Time Frame: CT hematoma volume at 36 +/- 12 hours compared to baseline (within 6 hours of last seen normal)
|
Correlate baseline TEG values (within 6 hours of last seen normal) with hematoma enlargement
|
CT hematoma volume at 36 +/- 12 hours compared to baseline (within 6 hours of last seen normal)
|
Hemorrhagic transformation after IV tPA
Time Frame: Any bleeding on post tPA imaging 36 hours +/- 12 hrs after stroke onset
|
Correlate baseline TEG values (within 4.5 hours of last seen normal) with hemorrhagic transformation or hemorrhage on CT 36 hours after stroke onset
|
Any bleeding on post tPA imaging 36 hours +/- 12 hrs after stroke onset
|
Arterial recanalization after IV tPA
Time Frame: Recanalization (TICI 2b or 3 flow) on imaging within 36 hours post IV tPA compared to pre-treatment
|
Correlate baseline TEG values (within 4.5 hours of last seen normal) with recanalization (TICI 2b or 3 flow) on imaging within 36 hours post IV tPA compared to pre-treatment
|
Recanalization (TICI 2b or 3 flow) on imaging within 36 hours post IV tPA compared to pre-treatment
|
Hyperdense Middle Cerebral Artery Sign (HDMCA)
Time Frame: HDMCA on baseline CT in patients receiving IV tPA within 4.5 hours of last seen normal
|
Correlate baseline TEG values (within 4.5 hours of last seen normal) with HDMCA on baseline CT imaging
|
HDMCA on baseline CT in patients receiving IV tPA within 4.5 hours of last seen normal
|
Collaborators and Investigators
Investigators
- Principal Investigator: James Grotta, M.D., The University of Texas Health Science Center, Houston
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MS-09-0156
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ischemic Stroke
-
Nordsjaellands HospitalRigshospitalet, Denmark; Metropolitan University CollegeCompletedTransient Ischemic Attack | Stroke, Ischemic | Stroke HemorrhagicDenmark
-
University of CalgaryThe George Institute for Global Health, AustraliaNot yet recruitingAcute Ischemic Stroke AIS | Stroke, Acute, Stroke Ischemic | Stroke AcuteCanada, Australia
-
Second Affiliated Hospital, School of Medicine,...Shanghai Zhongshan Hospital; First Affiliated Hospital of Wenzhou Medical University and other collaboratorsRecruitingAcute Ischemic Stroke and Transient Ischemic AttacksChina
-
Medtronic Cardiac Rhythm and Heart FailureMedtronic Bakken Research CenterCompletedCryptogenic Symptomatic Transient Ischemic Attack | Cryptogenic Ischemic StrokeNetherlands, United States, France, Belgium, Germany, Sweden, Italy, Austria, Canada, Denmark, Finland, Greece, Slovakia, Spain
-
Umbria Bioengineering TechnologiesRecruitingStroke, Ischemic | Stroke HemorrhagicItaly
-
University Hospital, BrestCompletedStroke, Ischemic | Stroke HemorrhagicFrance
-
BayerRecruitingAcute Non-cardioembolic Ischemic Stroke | Prevention of Ischemic Stroke | High-risk Transient Ischemic AttackUnited States, Switzerland, Belgium, Australia, Sweden, Canada, Taiwan, Spain, Korea, Republic of, Latvia, Israel, Malaysia, China, Greece, Japan, Turkey, Netherlands, Romania, United Kingdom, Portugal, Hungary, Italy, Brazil, France, S... and more
-
Sheffield Teaching Hospitals NHS Foundation TrustUnknownFatigue | Stroke, Ischemic | Stroke HemorrhagicUnited Kingdom
-
University of AlbertaCompletedTransient Ischemic Attack | Minor Ischemic StrokeCanada
-
Stephanie HarrisonActive, not recruitingTransient Ischemic Attack | Stroke, IschemicUnited Kingdom
Clinical Trials on Thromboelastography
-
University Hospitals, LeicesterCompletedPost-Dural Puncture Headache | Low Pressure HeadacheUnited Kingdom
-
Vanderbilt University Medical CenterWithdrawnCirrhosis, Liver | Coagulopathy | GastroIntestinal Bleeding
-
Rajiv Gandhi Cancer Institute & Research Center...Completed
-
Hôpital Armand TrousseauCompletedPost Partum Hemorrhage
-
University of PennsylvaniaPrinceton UniversityCompletedTrauma | Trauma Injury | CoagulopathyUnited States
-
Cardiochirurgia E.H.TerminatedBleeding | Blood TransfusionItaly
-
Tel-Aviv Sourasky Medical CenterUnknownLiver Cirrhosis | Coagulopathy
-
Western Galilee Hospital-NahariyaCompletedBariatric Patients Undergoing Bariatric SurgeryIsrael
-
Washington University School of MedicineOrthopedic Research and Education FoundationTerminatedNeuromuscular ScoliosisUnited States